Fonseca R - Search Results

1

Kidney Transplant in the Era of Modern Therapy for Multiple Myeloma.

Huskey JL, Heilman RL, Khamash H, Fonseca R. Huskey JL, et al. Among authors: fonseca r. Transplantation. 2018 Dec;102(12):1994-2001. doi: 10.1097/TP.0000000000002449. Transplantation. 2018. PMID: 30211830 Review.

2

Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma.

Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Therneau TM, Kyle RA, Litzow MR, Gertz MA, Greipp PR. Rajkumar SV, et al. Among authors: fonseca r. J Clin Oncol. 1999 May;17(5):1551-7. doi: 10.1200/JCO.1999.17.5.1551. J Clin Oncol. 1999. PMID: 10334543

3

Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma.

Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Lust JA, Greipp PR, Therneau TM, Kyle RA, Litzow MR, Gertz MA. Rajkumar SV, et al. Among authors: fonseca r. Bone Marrow Transplant. 1999 Jun;23(12):1261-6. doi: 10.1038/sj.bmt.1701787. Bone Marrow Transplant. 1999. PMID: 10414913 Clinical Trial.

4

Autologous stem cell transplantation for relapsed and primary refractory myeloma.

Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Lust JA, Greipp PR, Therneau TM, Kyle RA, Litzow MR, Gertz MA. Rajkumar SV, et al. Among authors: fonseca r. Bone Marrow Transplant. 1999 Jun;23(12):1267-72. doi: 10.1038/sj.bmt.1701805. Bone Marrow Transplant. 1999. PMID: 10414914 Clinical Trial.

5

Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.

Rajkumar S, Fonseca R, Lacy M, Witzig T, Lust J, Greipp P, Therneau T, Kyle R, Litzow M, Gertz M. Rajkumar S, et al. Among authors: fonseca r. Bone Marrow Transplant. 1999 Sep;24(5):497-503. doi: 10.1038/sj.bmt.1701943. Bone Marrow Transplant. 1999. PMID: 10482933

6

Bone marrow angiogenesis in multiple myeloma: effect of therapy.

Kumar S, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. Kumar S, et al. Among authors: fonseca r. Br J Haematol. 2002 Dec;119(3):665-71. doi: 10.1046/j.1365-2141.2002.03871.x. Br J Haematol. 2002. PMID: 12437642 Free article.

7

Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma.

Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Geyer SM, Iturria NL, Fonseca R, Hayman SR, Lust JA, Kyle RA, Greipp PR, Witzig TE, Rajkumar SV. Kumar S, et al. Among authors: fonseca r. Mayo Clin Proc. 2003 Jan;78(1):34-9. doi: 10.4065/78.1.34. Mayo Clin Proc. 2003. PMID: 12528875

8

Genomics in multiple myeloma: biology and clinical implications.

Chng WJ, Fonseca R. Chng WJ, et al. Among authors: fonseca r. Pharmacogenomics. 2005 Sep;6(6):563-73. doi: 10.2217/14622416.6.6.563. Pharmacogenomics. 2005. PMID: 16142997

9

Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.

Dingli D, Rajkumar SV, Nowakowski GS, Gertz MA, Dispenzieri A, Lacy MQ, Hayman S, Fonseca R, Lust JA, Kyle RA, Greipp PR, Witzig TE. Dingli D, et al. Among authors: fonseca r. Haematologica. 2005 Dec;90(12):1650-4. Haematologica. 2005. PMID: 16330438

10

Risk stratification of patients with newly diagnosed multiple myeloma: optimizing treatment based on pretreatment characteristics.

Chng WJ, Fonseca R. Chng WJ, et al. Among authors: fonseca r. Clin Lymphoma Myeloma. 2005 Nov;6(3):200-7. doi: 10.3816/CLM.2005.n.047. Clin Lymphoma Myeloma. 2005. PMID: 16354325 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,493 results

Search Page

Filters